Global Male Infertility Market By Treatment (Assisted Reproductive Technology & Varicocele Surgery and Medication), By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests), By Region, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Male Infertility Market
Market Report Description
The Global Male Infertility Market size is expected to reach $3.2 billion by 2026, rising at a market growth of 7.6% CAGR during the forecast period. Male infertility is the inability of a male to cause pregnancy in a fertile female. A male's fertility relies mainly on the quantity and quality of their sperms. If a man's sperm count is small or if the sperm is of poor quality, it would be difficult, and even impossible, for him to cause pregnancy. The problem of infertility is widespread. Male fertility includes the normal functioning of the hypothalamus, pituitary gland, and testes. Nonetheless, 40 percent-50 percent of cases have no identifiable cause and 30 percent-40 percent of cases are due to problems in the testes.
Global Male Infertility Market Size
Continuous R&D efforts are being made to better understand the idiopathic world of infertility. As a result, companies are investing in the development of root cause identification and targeted treatment devices. In addition, the production and commercialization of hormonal therapy are expected to fuel the demand for male infertility during the forecast period. Governments in different countries have taken steps to boost the recovery scenario for infertility-related therapies. In addition, improved safety of patient data due to standardization of legislation is expected to increase consumer demand for infertility treatment.
Advancements in medical testing and rising infertility in males are two of the main factors driving the demand for male infertility. In addition, lifestyle-associated disorders causing infertility, rising obesity, and the expanding aging population are likely to boost the market growth over the forecast period. In the U.S., one-third of cases of infertility are attributed to female factors, one third to male causes, and the other one third is uncertain.
Male Infertility Market Share
Free Valuable Insights: Global Male Infertility Market to reach a market size of $3.2 billion by 2026
ARTs are used to cure major factors responsible for male infertility. These factors range from sperm autoantibodies, viral orchitis, epididymal dysfunction, accessory gland infections, chemotherapy, to heat, trauma, and other idiopathic factors. High treatment costs and the requirement for several other treatment cycles are some of the key factors contributing to the growth of the segment. Growing spending on health care in developed countries, raising awareness of male infertility, and growing acceptance in middle and low-income countries are the main factors projected to drive the ART segment over the forecast period.
Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.
Recent Strategies Deployed in Male Infertility Market
- Jun-2020: Inspiration Healthcare signed an agreement to acquire S.L.E., a company engaged in designing and manufacturing ventilators for neonatal intensive care. The acquisition would help the company in becoming a leader in neonatal intensive care sector. Additionally, the acquisition would broaden its product portfolio and global distribution network.
- May-2020: Drager collaborated with Florida Hospital following which the latter company implemented the Babyleo TN500 IncuWarmer beds from the former company. The beds are in use in Neonatal Intensive Care Units (NICU) at three hospitals across the health system in Central Florida.
- Dec-2019: Inspiration Healthcare took over Viomedex, a medical device manufacturer. The acquisition broadened the company's product portfolio and provided growth opportunities to become a leader in neonatal intensive care.
- Mar-2018: GE Healthcare came into partnership with Amref Health Africa. The partnership was aimed to develop a range of in-country health care service collaborations throughout reproductive, non-communicable disease, maternal, water, sanitation, & hygiene, newborn & child health, and safe surgery.
- Nov-2017: Natus Medical announced its collaboration with Aspect Imaging, the developer of compact high-performance MRI Systems. The collaboration was aimed to distribute Embrace Neonatal MRI system in North America.
- Jul-2017: Philips partnered with the historic San Giovanni Calibita Fatebenefratelli Hospital in Rome. The partnership was aimed to introduce state-of-the-art Family Centered Care (FCC) at the hospital. The partnership enabled the San Giovanni Calibita to deliver developmentally focused, family centered mother-and-child care of the highest clinical quality.
- Feb-2017: Dragerwerk launched IncuWarmer Babyleo TN500. It offers optimal thermoregulation in closed care, open care, and transition. This device provides a stable micro-environment for the premature baby.
- Feb-2016: Medtronic acquired Bellco, a company that has developed therapies and systems for the treatment of multiple organ failure, renal failure, and sepsis. The acquisition broadened Medtronic's portfolio and helped it in providing comprehensive care for dialysis patients.
Scope of the Male Infertility Market Analysis
- Assisted Reproductive Technology & Varicocele Surgery
- DNA Fragmentation Technique
- Oxidative Stress Analysis
- Computer Assisted Semen Analysis
- Microscopic Examination
- Sperm Agglutination
- Sperm Penetration Assay
- Other Tests
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Sanofi S.A.
- Bayer AG
- Cadila Healthcare Ltd. (Zydus Cadila)
- Endo International PLC
- Aytu BioScience, Inc.
- Vitrolife AB
- SCSA Diagnostics, Inc.
- Andrology Solutions Limited
- Halotech DNA SL
- Intas Pharmaceutical Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Male Infertility Market Related Reports:
How valuable the male infertility market be in the future?
According to a new report published by KBV Research, The male infertility market is projected to reach USD 3.2 billion by 2026.
What are the key factors drive male infertility industry?
The major factors that are anticipated to drive the male infertility industry include increasing incidence of infertility, growing demand for assisted reproductive technologies [ART], and changing lifestyle, increasing ages, excess consumption of alcohol and drugs, environmental factors and genetic abnormalities.
Which region shows largest market share in male infertility market in 2019?
The North America dominated the regional segment of the male infertility market and held the largest share of total revenue in 2019.
Who are the leading players in male infertility market?
Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.